Published in J Acquir Immune Defic Syndr on December 01, 2010
A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health (2014) 1.67
Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One (2013) 1.61
The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood) (2011) 1.29
Methamphetamine use is associated with childhood sexual abuse and HIV sexual risk behaviors among patrons of alcohol-serving venues in Cape Town, South Africa. Drug Alcohol Depend (2012) 1.20
HIV infection and risk of overdose: a systematic review and meta-analysis. AIDS (2012) 1.18
Not just the needle: the state of HIV-prevention science among substance users and future directions. J Acquir Immune Defic Syndr (2013) 1.16
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs (2012) 0.99
High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend (2013) 0.95
HealthCall: technology-based extension of motivational interviewing to reduce non-injection drug use in HIV primary care patients - a pilot study. AIDS Care (2012) 0.93
Improving public health through access to and utilization of medication assisted treatment. Int J Environ Res Public Health (2011) 0.90
Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network. Subst Abuse Rehabil (2011) 0.90
Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective. J Acquir Immune Defic Syndr (2010) 0.90
Examining the spatial distribution of law enforcement encounters among people who inject drugs after implementation of Mexico's drug policy reform. J Urban Health (2015) 0.90
Opioid analgesic misuse is associated with incomplete antiretroviral adherence in a cohort of HIV-infected indigent adults in San Francisco. AIDS Behav (2014) 0.89
Mortality among methadone maintenance clients in China: a six-year cohort study. PLoS One (2013) 0.89
A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia. AIDS (2013) 0.88
Concurrent substance abuse is associated with sexual risk behavior among adults seeking treatment for prescription opioid dependence. Am J Addict (2013) 0.87
Predictors of continued HIV-risk behaviors among drug users in methadone maintenance therapy program in China--a prospective study. Harm Reduct J (2013) 0.86
Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend (2014) 0.84
Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. Am J Public Health (2013) 0.83
Nonmedical prescription drug users in private vs. public substance abuse treatment: a cross sectional comparison of demographic and HIV risk behavior profiles. Subst Abuse Treat Prev Policy (2014) 0.82
Setting the bar high or setting up to fail? Interpretations and implications of the EXPLORE Study (HPTN 015). AIDS Behav (2014) 0.82
Adolescent health-risk sexual behaviors: effects of a drug abuse intervention. AIDS Behav (2011) 0.82
Participant and staff experiences in a peer-delivered HIV intervention with injection drug users. J Empir Res Hum Res Ethics (2014) 0.82
Methadone maintenance for HIV positive and HIV negative patients in Kyiv: acceptability and treatment response. Drug Alcohol Depend (2014) 0.81
Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend (2014) 0.80
Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med (2013) 0.79
Ethnic- and gender-specific differences in the prevalence of HIV among patients in opioid maintenance treatment-a case register analysis. Harm Reduct J (2014) 0.79
'South Asian cocktail'--the concurrent use of opioids, benzodiazepines and antihistamines among injecting drug users in Nepal and associations with HIV risk behaviour. Harm Reduct J (2014) 0.79
Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. BMC Infect Dis (2016) 0.79
Substance use disorders and HIV/AIDS prevention and treatment intervention: research and practice considerations. Soc Work Public Health (2013) 0.78
Factors associated with inability to access addiction treatment among people who inject drugs in Vancouver, Canada. Subst Abuse Treat Prev Policy (2016) 0.78
NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs. Am J Drug Alcohol Abuse (2011) 0.78
Advantages of Joint Modeling of Component HIV Risk Behaviors and Non-Response: Application to Randomized Trials in Cocaine-Dependent and Methamphetamine-Dependent Populations. Front Psychiatry (2011) 0.78
The use of the Risky Sex Scale among adolescents receiving treatment services for substance use problems: factor structure and predictive validity. J Subst Abuse Treat (2012) 0.77
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr (2015) 0.77
HIV prevention for people who use substances: evidence-based strategies. J Food Drug Anal (2013) 0.76
HIV testing and sero-prevalence among methamphetamine users seeking substance abuse treatment in Cape Town. Drug Alcohol Rev (2015) 0.75
The Prevalence of HIV Risk Behaviors among Felony Drug Court Participants. Drug Court Rev (2012) 0.75
Substance use and hepatitis C: an ecological momentary assessment study. Health Psychol (2014) 0.75
Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia. PLoS One (2012) 0.75
Involvement in Specific HIV Risk Practices among Men Who Use the Internet to Find Male Partners for Unprotected Sex. J Addict (2013) 0.75
HIV prevention, treatment, and care for people who inject drugs. J Infect Dis (2013) 0.75
HIV Risk Behavior Among Methamphetamine Users Entering Substance Abuse Treatment in Cape Town, South Africa. AIDS Behav (2016) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med (1981) 7.35
Risk factors for HIV infection among men who have sex with men. AIDS (2006) 7.01
The effects of psychosocial services in substance abuse treatment. JAMA (1993) 5.87
Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet (2004) 5.57
Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr (1993) 5.08
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS (1994) 3.67
Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med (2006) 3.64
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 3.52
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend (2000) 3.18
Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav (1988) 3.14
Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction (2008) 3.01
Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend (2004) 2.97
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Drug abuse treatment as AIDS prevention. Public Health Rep (1998) 2.80
Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial. J Acquir Immune Defic Syndr (2008) 2.78
An individually tailored intervention for HIV prevention: baseline data from the EXPLORE Study. Am J Public Health (2003) 2.72
Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction (2010) 2.65
Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis (2009) 2.26
Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend (1996) 2.13
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis (2006) 2.08
Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction (2005) 2.05
Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep (1998) 1.98
Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. J Subst Abuse Treat (2009) 1.95
Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend (2006) 1.92
Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS (2009) 1.89
Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy (2007) 1.88
Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev (2008) 1.79
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health (2000) 1.78
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction (2008) 1.76
Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med (2005) 1.73
Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend (2003) 1.68
Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis (2009) 1.65
Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat (2004) 1.64
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat (2006) 1.63
Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy (2009) 1.63
Sexual risk among injection drug users recruited from syringe exchange programs in California. Sex Transm Dis (2005) 1.62
Global epidemiology of HIV. Curr Opin HIV AIDS (2009) 1.52
Substance use among men who have sex with men: comparison with a national household survey. J Acquir Immune Defic Syndr (2001) 1.50
Preventing HIV transmission with antiretrovirals. Bull World Health Organ (2009) 1.50
Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis (2010) 1.46
The Chinese government's response to drug use and HIV/AIDS: a review of policies and programs. Harm Reduct J (2010) 1.44
Outpatient substance abuse treatment and HIV prevention: an update. J Subst Abuse Treat (2006) 1.43
Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health (2007) 1.41
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat (2007) 1.38
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry (1999) 1.34
HIV infection among injection-drug users - 34 states, 2004-2007. MMWR Morb Mortal Wkly Rep (2009) 1.30
Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis (2005) 1.24
Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend (2003) 1.23
HIV prevention among injection drug users: the need for integrated models. J Urban Health (2003) 1.22
Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care (2002) 1.20
Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict (1995) 1.20
Impact of methadone on drug use and risky sex in China. J Subst Abuse Treat (2007) 1.19
Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med (1990) 1.19
Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev (2010) 1.19
Intravenous drug users and the acquired immune deficiency syndrome. Public Health Rep (1984) 1.18
Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-control study. AIDS Care (1994) 1.17
Human immunodeficiency virus prevention and the potential of drug abuse treatment. Clin Infect Dis (2003) 1.16
Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat (2003) 1.15
HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care (2009) 1.14
Reducing sex under the influence of drugs or alcohol for patients in substance abuse treatment. Addiction (2010) 1.10
Outcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men. J Subst Abuse Treat (2008) 1.10
Substance use and high risk sexual behaviors among women in psychosocial outpatient and methadone maintenance treatment programs. Am J Drug Alcohol Abuse (2009) 1.09
Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis (2006) 1.03
Condom attitudes and behaviors among injection drug users participating in California syringe exchange programs. AIDS Behav (2005) 1.03
Measuring the impact of the global response to the AIDS epidemic: challenges and future directions. J Acquir Immune Defic Syndr (2009) 0.99
Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV. Drug Alcohol Depend (2008) 0.96
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr (2010) 0.95
Availability of HIV-related health services in adolescent substance abuse treatment programs. AIDS Care (2009) 0.94
Methamphetamine use and other club drug use differ in relation to HIV status and risk behavior among gay and bisexual men. Sex Transm Dis (2009) 0.91
HIV/AIDS and drug abuse: epidemiology and prevention. J Addict Dis (1998) 0.86
Does intensive outpatient cocaine treatment reduce AIDS risky behaviors? J Addict Dis (1998) 0.80
Drug abuse treatment process: a review of the literature. Int J Addict (1985) 0.77
An international consensus for assessing internet gaming disorder using the new DSM-5 approach. Addiction (2014) 8.38
What's in a word? Addiction versus dependence in DSM-V. Am J Psychiatry (2006) 8.22
Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend (2005) 4.65
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology (2005) 3.53
Internet gaming disorder and the DSM-5. Addiction (2013) 3.46
Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial. JAMA (2013) 3.25
Decreased gray matter concentration in the insular, orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol Psychiatry (2002) 3.22
Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2006) 3.06
Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol (2007) 2.98
DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry (2013) 2.89
Limbic activation to cigarette smoking cues independent of nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacology (2007) 2.73
Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry (2007) 2.60
The status of disulfiram: a half of a century later. J Clin Psychopharmacol (2006) 2.48
Issues for DSM-V: should obesity be included as a brain disorder? Am J Psychiatry (2007) 2.48
A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry (2010) 2.34
MET meets the real world: design issues and clinical strategies in the Clinical Trials Network. J Subst Abuse Treat (2002) 2.08
Prelude to passion: limbic activation by "unseen" drug and sexual cues. PLoS One (2008) 2.07
Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry (2007) 2.07
The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol (2006) 2.00
The availability of web sites offering to sell opioid medications without prescriptions. Am J Psychiatry (2006) 1.93
Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis (2007) 1.82
Racial/ethnic variations in substance-related disorders among adolescents in the United States. Arch Gen Psychiatry (2011) 1.80
A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend (2004) 1.75
Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci (2011) 1.74
The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med (2007) 1.70
Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. J Womens Health (Larchmt) (2008) 1.67
Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat (2006) 1.63
Comparing attentional bias to smoking cues in current smokers, former smokers, and non-smokers using a dot-probe task. Drug Alcohol Depend (2002) 1.56
Buprenorphine use: the international experience. Clin Infect Dis (2006) 1.55
Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend (2003) 1.50
How do prescription opioid users differ from users of heroin or other drugs in psychopathology: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Addict Med (2011) 1.49
Effects of varenicline on smoking cue–triggered neural and craving responses. Arch Gen Psychiatry (2011) 1.45
Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict Behav (2002) 1.44
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Retrospective study: influence of menstrual cycle on cue-induced cigarette craving. Nicotine Tob Res (2004) 1.37
Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat (2004) 1.35
Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry (2013) 1.33
DAT genotype modulates brain and behavioral responses elicited by cigarette cues. Neuropsychopharmacology (2008) 1.31
Errors in assessing DSM-IV substance use disorders. Arch Gen Psychiatry (2007) 1.31
The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend (2009) 1.30
An item response theory modeling of alcohol and marijuana dependences: a National Drug Abuse Treatment Clinical Trials Network study. J Stud Alcohol Drugs (2009) 1.27
Subtypes of nonmedical opioid users: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend (2010) 1.27
A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet (2003) 1.25
Early data from Project Engage: a program to identify and transition medically hospitalized patients into addictions treatment. Addict Sci Clin Pract (2012) 1.23
Economic costs of nonmedical use of prescription opioids. Clin J Pain (2011) 1.22
Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States. AIDS Care (2013) 1.18
Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry (2012) 1.18
Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat (2007) 1.18
A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend (2006) 1.17
Dopamine transporter genotype modulation of neural responses to smoking cues: confirmation in a new cohort. Addict Biol (2011) 1.16
A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res (2008) 1.15
Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend (2003) 1.15
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry (2007) 1.14
A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage (2006) 1.13
Alcohol potentiates hepatitis C virus replicon expression. Hepatology (2003) 1.11
A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav (2007) 1.11
A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat (2012) 1.10
Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry (2011) 1.10
A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol (2007) 1.10
Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin Exp Res (2002) 1.06
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol (2006) 1.06
Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry (2011) 1.05
Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology (2008) 1.05
Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. J Psychiatr Res (2011) 1.04
Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. Am J Addict (2004) 1.03
A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend (2013) 1.03
Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction (2010) 1.02
The Diversion of Ultram, Ultracet, and generic tramadol HCL. J Addict Dis (2006) 1.02
Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf (2005) 1.01
A comparison of the effects of 6-beta naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacol Biochem Behav (2002) 1.00
Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment. J Clin Psychiatry (2010) 0.99
Treatment use and barriers among adolescents with prescription opioid use disorders. Addict Behav (2011) 0.99
Gender and racial/ethnic differences in addiction severity, HIV risk, and quality of life among adults in opioid detoxification: results from the National Drug Abuse Treatment Clinical Trials Network. Subst Abuse Rehabil (2010) 0.98
Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Subst Abuse Rehabil (2011) 0.98
Rationale for changes in DSM-5. J Stud Alcohol Drugs (2012) 0.98
Detecting smoking following smoking cessation treatment. Drug Alcohol Depend (2002) 0.98
Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet (2005) 0.97
Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. J Subst Abuse Treat (2010) 0.97
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus (2012) 0.97
The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders. Neuropsychopharmacology (2011) 0.96
Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database. J Psychiatr Res (2011) 0.96
Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol (2006) 0.95
Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend (2009) 0.95
HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr (2010) 0.95
A VBM study demonstrating 'apparent' effects of a single dose of medication on T1-weighted MRIs. Brain Struct Funct (2013) 0.94
A randomized trial of oral naltrexone for treating opioid-dependent offenders. Am J Addict (2010) 0.94
Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil (2011) 0.94
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry (2006) 0.93
Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict (2008) 0.93
Reward-related brain response and craving correlates of marijuana cue exposure: a preliminary study in treatment-seeking marijuana-dependent subjects. J Addict Med (2013) 0.93
Neural responses to subliminally presented cannabis and other emotionally evocative cues in cannabis-dependent individuals. Psychopharmacology (Berl) (2013) 0.92
Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend (2013) 0.91
A dimensional approach to understanding severity estimates and risk correlates of marijuana abuse and dependence in adults. Int J Methods Psychiatr Res (2012) 0.91
Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. Drug Alcohol Depend (2011) 0.90
Co-occurring amphetamine use and associated medical and psychiatric comorbidity among opioid-dependent adults: results from the Clinical Trials Network. Subst Abuse Rehabil (2011) 0.90
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav (2012) 0.90
A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr Genet (2005) 0.90